If you have started researching GLP-1 medication for weight loss in India, you have run into four names — Mounjaro, Wegovy, Ozempic, and now a wave of generic semaglutide brands. They are not interchangeable. They contain different molecules, cost very different amounts, and produce different average results.
This guide compares them the way a doctor would when deciding what to prescribe: by molecule, by evidence, by cost in Indian rupees, and by how they fit a specific person.
This is general information, not medical advice. GLP-1 medications are prescription-only in India and require evaluation by a licensed doctor.
The Short Version
| Mounjaro | Wegovy | Ozempic / generic semaglutide | |
|---|---|---|---|
| Molecule | Tirzepatide (GIP + GLP-1) | Semaglutide 2.4 mg (GLP-1) | Semaglutide (GLP-1) |
| Maker | Eli Lilly | Novo Nordisk | Novo Nordisk / Indian generics |
| Approved in India for | Weight management and type 2 diabetes | Weight management | Type 2 diabetes (Ozempic); generics vary |
| Average weight loss in trials | ~20–21% over 72 weeks | ~15% over 68 weeks | ~15% over 68 weeks |
| Approx. monthly cost (2026) | ₹13,000–₹26,000 | ₹5,600–₹16,400 | ₹1,300–₹4,200 (generics) |
| Format | Vial or pen, weekly injection | Pre-filled pen, weekly injection | Pen, weekly injection (or oral for Rybelsus) |
The rest of this article explains what sits behind those rows.
What Each One Actually Is
Mounjaro (tirzepatide)
Mounjaro is Eli Lilly's brand name for tirzepatide. It launched in India in March 2025. Tirzepatide is a dual agonist: it activates both the GLP-1 receptor and the GIP receptor. Both are gut hormones involved in appetite regulation, insulin response, and how full you feel after eating. The dual mechanism is the leading theory for why tirzepatide produces larger average weight loss than semaglutide in head-to-head data.
In India it is sold as single-dose vials (2.5 mg and 5 mg) and, more recently, as a multi-dose KwikPen. It is taken once a week by subcutaneous injection, starting at 2.5 mg and increasing every four weeks as tolerated, up to a maximum of 15 mg.
Wegovy (semaglutide 2.4 mg)
Wegovy is Novo Nordisk's brand name for semaglutide dosed specifically for weight management — up to 2.4 mg weekly. It launched in India in June 2025. Semaglutide is a single GLP-1 receptor agonist. It slows gastric emptying, reduces appetite, and lowers "food noise" — the constant background pull toward eating.
Wegovy comes as a pre-filled single-use pen in five ascending strengths (0.25, 0.5, 1.0, 1.7, 2.4 mg). You step up roughly every four weeks. In April 2026, Novo Nordisk cut Wegovy's India price substantially in response to generic competition.
Ozempic and generic semaglutide
Ozempic is also semaglutide, but it is Novo Nordisk's brand for type 2 diabetes, dosed up to 2.0 mg. It is widely known internationally as a weight-loss drug because doctors prescribed it off-label before Wegovy existed. Ozempic is not formally marketed for weight loss in India, and importing it for that purpose is not a reliable or advisable route.
The bigger 2026 development is generic semaglutide. Novo Nordisk's core Indian patent on semaglutide expired in March 2026, and more than ten DCGI-approved Indian brands (from companies including Dr Reddy's, Sun Pharma, Cipla, Zydus, and others) have since launched. These are the same molecule as Wegovy and Ozempic, sold at a fraction of the price — roughly ₹1,300 to ₹4,200 per month depending on brand and dose.
Rybelsus is oral semaglutide (a daily tablet), approved for diabetes. Absorption is lower and more finicky than the injection, and the weight-management evidence base is smaller.
Efficacy: What the Trials Show
Weight-loss drugs are best compared using their large registration trials, where "percent of starting body weight lost" is the standard measure.
Semaglutide 2.4 mg — the STEP 1 trial. Adults without diabetes lost an average of about 14.9% of body weight over 68 weeks, versus 2.4% on placebo, alongside lifestyle support.
Tirzepatide — the SURMOUNT-1 trial. Adults without diabetes lost an average of about 15% at the 5 mg dose, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks.
Head to head — the SURMOUNT-5 trial. Tirzepatide was compared directly against semaglutide 2.4 mg. Tirzepatide produced roughly 20% average weight loss versus roughly 14% for semaglutide.
So on averages, tirzepatide wins on magnitude. But two caveats matter:
- These are averages. Individual response varies widely. Plenty of people reach their goal on semaglutide, and some people do not tolerate tirzepatide's higher doses.
- The trials paired the drug with structured lifestyle support — diet, activity, and regular check-ins. The drug alone, with no change to how you eat or train, underperforms the trial numbers.
Cost in India (2026)
Prices move, and every clinic and pharmacy prices slightly differently. As of 2026 the rough monthly ranges are:
- Mounjaro: about ₹13,000 per month at the 2.5 mg starting dose, rising to about ₹26,000 per month at 15 mg. Vials generally work out cheaper per dose than the KwikPen. Tirzepatide remains under patent in India, so there are no generic versions and prices are unlikely to fall sharply soon.
- Wegovy: after the April 2026 price cut, roughly ₹5,600 per month at 0.25 mg, rising to around ₹15,000–₹16,400 per month at the full 2.4 mg dose.
- Generic semaglutide: roughly ₹1,300 to ₹4,200 per month depending on brand and dose. This is the cheapest route to the semaglutide molecule.
A note on the maintenance dose: your first month or two is at a low starting dose and costs less. Budget for the dose your doctor expects you to settle on, not the introductory one.
Side Effects
The side-effect profiles are broadly similar because both molecules act on the GLP-1 pathway:
- Nausea — the most common, usually worst in the first week after a dose increase, and usually settling within days.
- Constipation or diarrhoea
- Reduced appetite and early fullness — this is the intended effect, but it can tip into eating too little
- Fatigue, especially early
- Reflux and burping
Serious risks are uncommon but real, and are the reason a doctor screens you first: pancreatitis, gallbladder problems, and a boxed warning about a rare thyroid tumour seen in rodent studies (which is why a personal or family history of medullary thyroid carcinoma or MEN2 rules the drugs out).
At the highest doses, some data suggest tirzepatide causes marginally more gastrointestinal upset than semaglutide, but for most people both are manageable with slow dose escalation and simple food adjustments.
The Problem None of Them Solve on Their Own
All three drugs share the same two weaknesses:
Weight regain after stopping. In the STEP 1 trial extension, participants regained about two-thirds of their lost weight within a year of stopping semaglutide. The drug suppresses appetite while you take it; it does not rewire your habits. What happens when you stop a GLP-1 covers this in detail.
Muscle loss. Roughly 25–40% of the weight lost on a GLP-1 can be lean mass if you do nothing to protect it. That means a smaller, weaker body and a lower metabolic rate — which makes regain easier. Resistance training and adequate protein change this outcome substantially. How to keep muscle on a GLP-1 goes deeper.
This is why the molecule you choose is only part of the decision. What wraps around it — nutrition, strength training, side-effect management, and a plan for coming off — determines whether the result lasts.
How Coachbase GLP Approaches This
Coachbase GLP is a doctor-led program built around a GLP-1 prescription, not a pharmacy that ships a drug in a box. A licensed physician reviews your history and decides whether medication is appropriate and, if so, which molecule and dose. From there:
- Medication is dispensed by registered pharmacy partners and delivered cold-chain.
- A protein-first nutrition plan is built for a smaller appetite, so the weight you lose is fat rather than muscle.
- A resistance-training program runs from week one to protect lean mass.
- Your care team manages side effects and paces your dose.
- A structured taper steps the dose down while your habits step up, so the results belong to you and not the prescription.
Common Questions
Is Mounjaro better than Wegovy?
On average, tirzepatide (Mounjaro) produces larger weight loss than semaglutide (Wegovy) in head-to-head trials — roughly 20% versus 14% of body weight. But response is individual, semaglutide is significantly cheaper, and tolerability matters more than the trial average for any one person. The right choice is the one a doctor makes with your history, goals, and budget in view.
Is Ozempic available in India for weight loss?
Ozempic is approved in India for type 2 diabetes, not weight loss. Since March 2026, generic semaglutide from Indian manufacturers has been available and is the practical, affordable route to the semaglutide molecule. Wegovy is the branded semaglutide approved specifically for weight management.
How much does GLP-1 weight loss cost per month in India?
As of 2026, roughly ₹1,300–₹4,200 for generic semaglutide, ₹5,600–₹16,400 for Wegovy, and ₹13,000–₹26,000 for Mounjaro, depending on dose. A full breakdown is in what GLP-1 weight loss actually costs in India.
Which GLP-1 has the fewest side effects?
Both semaglutide and tirzepatide have similar side-effect profiles, dominated by early nausea that usually settles. Slow dose escalation is the single biggest factor in tolerability, regardless of molecule.
Can I switch from one to the other?
Yes, under medical supervision. People switch for cost, tolerability, or plateaued results. Switching involves restarting dose titration, so expect a short adjustment period.
The medication is the easy part to compare. The harder question is what you do with the window it opens. If you want a doctor to help you choose — and a program that makes the loss last — start with the assessment.